In one of the biggest breakthroughs in schizophrenia research in recent times, Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia. The study published today in Molecular Psychiatry has the potential to transform global schizophrenia research and open new avenues for developing targeted immune cell therapies.
One in every 100 Australians lives with schizophrenia. No single cause of schizophrenia has been identified, and this has prevented the development of a cure. The current treatments for schizophrenia are designed to suppress symptoms rather than target underlying causes of the disorder. These drugs only partially relieve symptoms and can produce unwanted side effects.
To recognise the significance of this discovery Professor Shannon Weickert says you first need to understand most scientists have had a long held belief that immune cells were independent from the brain pathology in psychotic illnesses.
“In our study, we challenged this assumption that immune cells were independent of the brain in psychiatric illness and made an exciting discovery. We identified immune cells as a new player in the brain pathology of schizophrenia,” said Professor Shannon Weickert.
Current schizophrenia research has focused on the status of three brain cells: the neurons; the glial cells, which support the neurons; and the endothelial cells, which coat the blood vessels. Employing new molecular techniques allowed Professor Shannon Weickert and her team to identify the presence of a fourth cell, the macrophage, a type of immune cell in the brain tissue of people with schizophrenia who show high levels of inflammation.
Professor Shannon Weickert said immune cells have previously been ignored as they had long been viewed simply as travelers just thought to be passing by, undertaking surveillance work. They have never been a suspect until now.
“To find immune cells along the blood brain barrier in increased amounts in people with schizophrenia is an exciting discovery. It suggests immune cells themselves may be producing these inflammatory signals in the brains of people living with schizophrenia,” said Professor Shannon Weickert.
“We have observed in people with schizophrenia, the glial cells, one of the local residents, become inflamed and produce distress signals which change the status of the endothelial cells.
“We think this may cause the endothelial cells to extend sticky tentacles, so when the immune cells travel by some are captured. These cells may transmigrate across the blood brain barrier entering the brain in greater amounts in some people with schizophrenia compared to people without the disorder.”
This discovery shows that specific immune cells are in the brains of some people with schizophrenia in close enough proximity to the neurons to do damage.
Professor Peter Schofield, CEO of NeuRA said this innovative new research has the ability to alter the way in which we may be able to diagnose and treat schizophrenia.
“This breakthrough demonstrates the value of the NSW Government’s support for Professor Shannon Weickert as NSW Chair of Schizophrenia Research, which has delivered new insights that the community seeks,” said Professor Schofield.
Professor Shannon Weickert is encouraging a cross-collaborative approach between neuroscientists and immunologists globally, to work together to develop treatments targeting this abnormal immune pathology of schizophrenia.
“This opens whole new avenues for therapy, because it suggests that the pathology of schizophrenia could be within the immune cells and the immune cells could be contributing to the symptoms of schizophrenia,” said Professor Shannon Weickert.
Professor Shannon Weickert is uniquely motivated in her work, with her twin-brother being diagnosed with schizophrenia when he was 17 years old.
Learn more: Schizophrenia breakthrough
The Latest on: Schizophrenia
via Google News
The Latest on: Schizophrenia
- New discovery could be life changing for people with schizophreniaon June 4, 2020 at 12:58 pm
There's still a lot of questions. Would people want to know what's coming? Or the risks? Or the stigma? But for now, it's a big step, using big data, possibly leading to big medical breakthroughs.
- Schizophrenia Drugs Market Size, Share, Growth, Trends, Sales, Consumption, Production, Demand and Forecast to 2027on June 4, 2020 at 5:01 am
The research report of the global Schizophrenia Drugs market provides in-depth insights to ease decision making or to find relevant information. The report comprises various entities inclusive of ...
- One-day tropisetron treatment improves neurocognitive function in schizophreniaon June 1, 2020 at 7:25 am
Impaired neurocognitive function is a core feature of schizophrenia (SCZ). Sensory gating is a mechanism that filters stimuli, suppresses irrelevant stimuli and protects the integrity of cognitive ...
- What Nobody Told Me About Schizophreniaon June 1, 2020 at 2:25 am
The writer describes some of the challenges and successes she's found in her life after being diagnosed with schizophrenia.
- The Visual Word Form Area compensates for auditory working memory dysfunction in schizophreniaon June 1, 2020 at 2:12 am
Auditory working memory impairments feature prominently in schizophrenia. However, the existence of altered and perhaps compensatory neural dynamics, sub-serving auditory working memory, remains ...
- Minerva Schizophrenia-Drug Trial Misses Key Endpointson May 29, 2020 at 8:50 am
Roluperidone, a Minerva Neurosciences schizophrenia-drug candidate, failed to meet its key endpoints. But the company is undaunted.
- Minerva's schizophrenia drug misses main goal in study; shares tumbleon May 29, 2020 at 7:09 am
Minerva intends to consult with the U.S. Food and Drug Administration about the next steps of development, it said in a statement. Schizophrenia, which affects about 2.4 million adults in the United ...
- Long-acting antipsychotics safe, effective for in-hospital schizophrenia therapy initiationon May 29, 2020 at 6:24 am
Aristada Initio and Invega Sustenna appeared well tolerated and effective for initiating in-hospital schizophrenia treatment and continuing outpatient treatment, according to a study published in ...
- Keep schizophrenia affected people away from ‘information overload’ related to COVID-19on May 29, 2020 at 4:29 am
Throughout history, popular media and books have portrayed schizophrenia as a sign of lunacy and abnormality. On the contrary, with proper treatment and care more than two-thirds of schizophrenia ...
via Bing News